TrialSignal
Clinical trial intelligence report
A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Subjects With Symptoms of Common Cold
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03005067
Status
COMPLETED
Phase
PHASE2
Sponsor
GlaxoSmithKline
Executive brief
Investment-Ready Snapshot
This study will be conducted in adult participants with symptoms of common cold assessing if 1146A nasal spray reduces the severity of symptoms of the common cold compared to placebo. The study will also evaluate the safety of 1146A compared to placebo.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03005067
Indication
Common Cold
Modality
small molecule
Target
Carbomer 980 (1146A), Placebo
Intervention
Carbomer 980 (1146A), Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.